Drugs / NVDX3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06532253 | Aug 2024 → Mar 2036 expected | spondylolisthesis | Novadip Biosciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05961956 | Oct 2023 → Apr 2026 overdue | spondylolisthesis | Novadip Biosciences | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05987033 | Aug 2023 → Dec 2024 | — | Novadip Biosciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-22 | Novadip Biosciences | Results Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogenic product, in spine fusion novadip.com ↗
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces positive results from its NVDX3 program, an allogenic bone grafting material created from human osteogenic adipose tissue-derived mesenchymal stem cells (ASCs). |
| 2025-02-20 | Novadip Biosciences | Results Novadip shares positive 12-month results from phase 1b/2a trial with NVDX3 in trauma novadip.com ↗
At the 12-month follow-up visit, 100% of patients had bone union of their fractures, regardless of age and complexity of fractures treated, with the majority of patients achieving this by the six-month visit. |
| 2024-11-22 | Novadip Biosciences | Regulatory Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion novadip.com ↗
The FDA-approved IND study is a phase 2b/3 trial assessing the efficacy of NVDX3 compared to standard-of-care treatments in level two cervical spine fusion. |
| 2024-10-24 | Novadip Biosciences | Results Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative novadip.com ↗
Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, today announces positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-22 | Novadip Biosciences | Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogenic product, in spine fusion novadip.com ↗ |
| 2025-02-20 | Novadip Biosciences | Novadip shares positive 12-month results from phase 1b/2a trial with NVDX3 in trauma novadip.com ↗ |
| 2024-11-22 | Novadip Biosciences | Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion novadip.com ↗ |
| 2024-10-24 | Novadip Biosciences | Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative novadip.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVDX3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05987033 ↗ |
| Modality | Other / unclassified | “Long-term Safety Bucket Trial with NVDX3, an Osteogenic Implant of Human Allogenic Origin.” NCT06532253 ↗ |
| Route | Other | “NVDX3 is implanted during a single surgical intervention.” NCT05961956 ↗ |